Fusion Antibodies (LON:FAB) Trading Down 5.9%

Shares of Fusion Antibodies plc (LON:FAB) dropped 5.9% during mid-day trading on Wednesday . The stock traded as low as GBX 3.06 ($0.04) and last traded at GBX 3.20 ($0.04). Approximately 839,913 shares were traded during trading, a decline of 20% from the average daily volume of 1,055,250 shares. The stock had previously closed at GBX 3.40 ($0.04).

Fusion Antibodies Stock Performance

The stock has a 50-day moving average of GBX 3.23 and a 200 day moving average of GBX 3.57. The firm has a market capitalization of £3.05 million, a P/E ratio of -38.44 and a beta of 0.49. The company has a debt-to-equity ratio of 3.23, a quick ratio of 2.36 and a current ratio of 3.26.

Insider Transactions at Fusion Antibodies

In other Fusion Antibodies news, insider Simon Gordon Douglas bought 150,000 shares of the stock in a transaction on Monday, July 22nd. The stock was purchased at an average price of GBX 3 ($0.04) per share, with a total value of £4,500 ($5,934.33). 11.27% of the stock is currently owned by corporate insiders.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.